MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia
Authors:
Open Access
- 15 February 2018
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (5) , 830-839
Abstract
Survival of children with relapsed acute lymphoblastic leukemia is poor and understanding mechanisms underlying resistance is essential in developing new therapy. Relapse-specific heterozygous deletions in MSH6, a crucial part of DNA Mismatch Repair, are frequently detected. Our aim was to determine whether MSH6 deletion results in a hypermutator phenotype associated with generation of secondary mutations involved in drug resistance or leads to a failure to initiate apoptosis directly in response to chemotherapeutic agents. We knocked down MSH6 in mismatch repair proficient cell lines (697 and UOCB1) and showed significant increases in IC50s to 6-Thioguanine & 6-Mercaptopurine (697: 26- and 9-fold; UOCB1: 5- and 8-fold) in vitro, as well as increased resistance to 6-Mercaptopurine treatment in vivo. No shift in IC50 was observed in deficient cells (Reh & RS4;11). 697 MSH6 knockdown resulted in increased DNA thioguanine nucleotide levels compared to non-targeted cells (3,070 versus 1,722 fmol/mg DNA) with no difference observed in mismatch repair deficient cells. Loss of MSH6 did not give rise to microsatellite instability in cells lines or clinical samples nor did it significantly increase mutation rate, but rather resulted in a defect in cell cycle arrest upon thiopurine exposure. MSH6 knockdown cells showed minimal activation of checkpoint regulator CHK1, ɣH2AX (DNA damage marker) and p53 levels upon treatment with thiopurines, consistent with intrinsic chemoresistance due to failure to recognize thioguanine nucleotide mismatching and initiate mismatch repair. Aberrant MSH6 adds to the list of alterations/mutations associated with acquired resistance to purine analogues emphasizing the importance of thiopurine therapy.Keywords
This publication has 50 references indexed in Scilit:
- Leukemic Blasts with the Paroxysmal Nocturnal Hemoglobinuria Phenotype in Children with Acute Lymphoblastic LeukemiaThe American Journal of Pathology, 2012
- Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesBlood, 2011
- Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cellsNature Medicine, 2011
- CREBBP mutations in relapsed acute lymphoblastic leukaemiaNature, 2011
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide ResistanceClinical Cancer Research, 2009
- Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemiaBlood, 2008
- Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant GliomaClinical Cancer Research, 2008
- Mechanisms and functions of DNA mismatch repairCell Research, 2007
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- ATR Kinase Activation Mediated by MutSα and MutLα in Response to Cytotoxic O6-Methylguanine AdductsMolecular Cell, 2006